NCT05276011
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below.
- Notable Primary and study completion pushed from Oct 2027 to Oct 2028
- Start date: Oct 2026 to Oct 2027
- Notable Primary and study completion dates: Oct 2026 to Oct 2027
- Start date: Oct 2025 to Oct 2026
- Notable Primary and study completion dates: Oct 2025 to Oct 2026
- Start date: Oct 2024 to Oct 2025
- Notable Primary and study completion dates: Oct 2024 to Oct 2025
- Start date: Oct 2023 to Oct 2024
- Notable Primary and study completion dates: Oct 2023 to Oct 2024
- Start date: Oct 2022 to Oct 2023
- Minor Secondary endpoints: details revised at 1 of 5 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in Hip Pain as Assessed by VAS
Timeframe: Baseline to Month 12
Secondary (5)
Hip Disability and Osteoarthritis Outcome Score (HOOS)
Timed Up and Go Test (TUG)
UCLA Activity Score
Joint Space Width (JSW) on standing X-ray
WOMAC® (Western Ontario and McMaster Universities Osteoarthritis Index) total score
Arms and interventions
Active Treatment (TG-C)Active comparator
TG-C at 1.0 x 10e7 cells per single 2 mL intraarticular injection
Active Treatment 2 (TG-C)Active comparator
TG-C at 3.0 x 10e6 cells per single 2 mL intraarticular injection
Placebo Control (Normal Saline)Placebo comparator
Normal saline, single 2 mL intraarticular injection
Biologicals: TG-C, Placebo Control